Skip to main content
Top
Published in: Journal of Radiation Oncology 3/2018

01-09-2018 | Original Research

The effects of treatment duration on outcomes of radiation treatment with high-dose-rate brachytherapy in the era of concurrent chemoradiation for cervical carcinoma

Authors: T. W. Chen, N. E. Wandrey, C. S. Ha, Tony Y. Eng

Published in: Journal of Radiation Oncology | Issue 3/2018

Login to get access

Abstract

Purpose

This study analyzes the effects of treatment prolongation using a patient population that primarily received HDR-ICBT (high-dose-rate intracavitary brachytherapy) during CCRT (cisplatin-based chemotherapy with radiation).

Methods

A retrospective review was performed of 214 patients who were diagnosed with cervical carcinoma and completed radiation therapy with LDR (low-dose-rate)-ICBT (77 patients) or HDR-ICBT (137 patients). Whole pelvic radiation therapy was followed by ICBT. LDR-ICBT was delivered in two to three insertions at an average of 85 Gy to point A. After 2000, the institution transitioned to using HDR-ICBT during CCRT. HDR-ICBT was delivered in four to seven insertions, 300 to 700 cGy per session prescribed to point A. Separate statistical analyses were conducted for the patients who received LDR-ICBT and the patients who received HDR-ICBT.

Results

The LDR-ICBT treatment group included 77 patients. The median TD (treatment duration) of 60 days was used as the cutoff for statistical analyses. Significantly increased pelvic recurrence in the patients treated for TD > 60 days compared to TD ≤ 60 days was observed. There was a significant difference in OS (overall survival) distributions. Upon univariate analysis, age at diagnosis > 51 years old, TD > 60 days, and stage were found to be significant prognostic factors, but on multivariate analysis, the only significant prognostic factors were age at diagnosis > 51 years old and TD > 60 days. The HDR-ICBT treatment group all received CCRT and included 137 patients. A range of TD cutoff thresholds from 60 to 78 days was used. There was a significant difference in CSS (cause-specific survival) between TD ≤ 77 days and TD > 77 days. There was no significant difference in local recurrence, distant metastases, and complications. Stage was the only prognostic factor found on multivariate analysis.

Conclusions

In the present era of HDR-ICBT with CCRT, radiation treatment longer than 8 weeks does not appear to make a significant impact on clinical outcomes. This is a retrospective analysis. Further studies are warranted.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M et al (2013) Cervical Cancer. In: Ferlay J, Soerjomataram I, Ervik M et al (eds) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, Lyon, France Ferlay J, Soerjomataram I, Ervik M et al (2013) Cervical Cancer. In: Ferlay J, Soerjomataram I, Ervik M et al (eds) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, Lyon, France
2.
go back to reference Huang Z, Mayr NA, Gao M, Lo SS, Wang JZ, Jia G, Yuh WTC (2012) Onset time of tumor repopulation for cervical cancer: first evidence from clinical data. Int J Radiat Oncol Biol Phys 84:478–484CrossRefPubMedPubMedCentral Huang Z, Mayr NA, Gao M, Lo SS, Wang JZ, Jia G, Yuh WTC (2012) Onset time of tumor repopulation for cervical cancer: first evidence from clinical data. Int J Radiat Oncol Biol Phys 84:478–484CrossRefPubMedPubMedCentral
3.
go back to reference Withers HR, Taylor JM, Maciejewski B (1988) The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131–146CrossRefPubMed Withers HR, Taylor JM, Maciejewski B (1988) The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131–146CrossRefPubMed
4.
go back to reference Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–1161CrossRefPubMed Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–1161CrossRefPubMed
5.
go back to reference Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143CrossRefPubMed Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143CrossRefPubMed
6.
go back to reference Peters WA 3rd, Liu PY, Barrett RJ 2nd et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613CrossRefPubMed Peters WA 3rd, Liu PY, Barrett RJ 2nd et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613CrossRefPubMed
7.
go back to reference Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153CrossRefPubMed Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153CrossRefPubMed
8.
go back to reference Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol 17:1339–1348CrossRefPubMed Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol 17:1339–1348CrossRefPubMed
9.
go back to reference Viani GA, Manta GB, Stefano EJ, de Fendi LI (2009) Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy—a meta-analysis of clinical trials. J Exp Clin Cancer Res 28:47CrossRefPubMedPubMedCentral Viani GA, Manta GB, Stefano EJ, de Fendi LI (2009) Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy—a meta-analysis of clinical trials. J Exp Clin Cancer Res 28:47CrossRefPubMedPubMedCentral
10.
go back to reference Scalliet P, Gerbaulet A, Dubray B (1993) HDR versus LDR gynecological brachytherapy revisited. Radiother Oncol 28:118–126CrossRefPubMed Scalliet P, Gerbaulet A, Dubray B (1993) HDR versus LDR gynecological brachytherapy revisited. Radiother Oncol 28:118–126CrossRefPubMed
11.
go back to reference Liu R, Wang X, Tian JH et al (2014) High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 10:CD007563 Liu R, Wang X, Tian JH et al (2014) High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 10:CD007563
12.
go back to reference Eifel PJ, Ho A, Khalid N, Erickson B, Owen J (2014) Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study. Int J Radiat Oncol Biol Phys 89:249–256CrossRefPubMed Eifel PJ, Ho A, Khalid N, Erickson B, Owen J (2014) Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study. Int J Radiat Oncol Biol Phys 89:249–256CrossRefPubMed
13.
go back to reference Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, Stitt JA, Thomadsen BR, Buchler DA (1995) The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 32:1301–1307CrossRefPubMed Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, Stitt JA, Thomadsen BR, Buchler DA (1995) The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys 32:1301–1307CrossRefPubMed
14.
go back to reference Lanciano RM, Pajak TF, Martz K, Hanks GE (1993) The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 25:391–397CrossRefPubMed Lanciano RM, Pajak TF, Martz K, Hanks GE (1993) The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 25:391–397CrossRefPubMed
15.
go back to reference Perez CA, Grigsby PW, Castro-Vita H, Lockett MA (1995) Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 32:1275–1288CrossRefPubMed Perez CA, Grigsby PW, Castro-Vita H, Lockett MA (1995) Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 32:1275–1288CrossRefPubMed
16.
go back to reference Fyles A, Keane TJ, Barton M, Simm J (1992) The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 25:273–279CrossRefPubMed Fyles A, Keane TJ, Barton M, Simm J (1992) The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 25:273–279CrossRefPubMed
17.
go back to reference Girinsky T, Rey A, Roche B, Haie C, Gerbaulet A, Randrianarivello H, Chassagne D (1993) Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 27:1051–1056CrossRefPubMed Girinsky T, Rey A, Roche B, Haie C, Gerbaulet A, Randrianarivello H, Chassagne D (1993) Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 27:1051–1056CrossRefPubMed
18.
go back to reference Viswanathan AN, Thomadsen B (2012) American brachytherapy society cervical cancer recommendations C, American brachytherapy S. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 11:33–46CrossRefPubMed Viswanathan AN, Thomadsen B (2012) American brachytherapy society cervical cancer recommendations C, American brachytherapy S. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 11:33–46CrossRefPubMed
19.
go back to reference Viswanathan AN, Beriwal S, De Los Santos JF et al (2012) American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 11:47–52CrossRefPubMedPubMedCentral Viswanathan AN, Beriwal S, De Los Santos JF et al (2012) American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 11:47–52CrossRefPubMedPubMedCentral
20.
go back to reference Chen SW, Liang JA, Yang SN, Ko HL, Lin FJ (2003) The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother Oncol 67:69–76CrossRefPubMed Chen SW, Liang JA, Yang SN, Ko HL, Lin FJ (2003) The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother Oncol 67:69–76CrossRefPubMed
21.
go back to reference Chatani M, Matayoshi Y, Masaki N, Inoue T (1997) High-dose rate intracavitary irradiation for carcinoma of the uterine cervix. The adverse effect of treatment prolongation. Strahlenther Onkol 173:379–384CrossRefPubMed Chatani M, Matayoshi Y, Masaki N, Inoue T (1997) High-dose rate intracavitary irradiation for carcinoma of the uterine cervix. The adverse effect of treatment prolongation. Strahlenther Onkol 173:379–384CrossRefPubMed
22.
go back to reference Lee LJ, Das IJ, Higgins SA, Jhingran A, Small W Jr, Thomadsen B, Viswanathan AN, Wolfson A, Eifel P, American Brachytherapy Society (2012) American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy. Brachytherapy 11:53–57CrossRefPubMed Lee LJ, Das IJ, Higgins SA, Jhingran A, Small W Jr, Thomadsen B, Viswanathan AN, Wolfson A, Eifel P, American Brachytherapy Society (2012) American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy. Brachytherapy 11:53–57CrossRefPubMed
23.
go back to reference Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, Yamada SD, Lee NK, Hasan Y (2013) The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 119:325–331CrossRefPubMed Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, Yamada SD, Lee NK, Hasan Y (2013) The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 119:325–331CrossRefPubMed
24.
go back to reference Hong J, Foote J, Broadwater G et al (2017) Data-derived treatment duration goal for cervical cancer: should 8 weeks remain the target in the era of concurrent chemoradiation? J Clin Oncol Clin Cancer Inform 1:1–15 Hong J, Foote J, Broadwater G et al (2017) Data-derived treatment duration goal for cervical cancer: should 8 weeks remain the target in the era of concurrent chemoradiation? J Clin Oncol Clin Cancer Inform 1:1–15
25.
go back to reference Shaverdian N, Gondi V, Sklenar KL, Dunn EF, Petereit DG, Straub MR, Bradley KA (2013) Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 86:562–568CrossRefPubMed Shaverdian N, Gondi V, Sklenar KL, Dunn EF, Petereit DG, Straub MR, Bradley KA (2013) Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 86:562–568CrossRefPubMed
26.
go back to reference Devlin PM (2016) Brachytherapy: applications and techniques. New York, Demos Medical Devlin PM (2016) Brachytherapy: applications and techniques. New York, Demos Medical
27.
go back to reference Eng TY, Chen T, Vincent J, Patel AJ, Clyburn V, Ha CS (2017) Persistent disparities in Hispanics with cervical cancer in a major city. J Racial Ethn Health Disparities 4:165–168CrossRefPubMed Eng TY, Chen T, Vincent J, Patel AJ, Clyburn V, Ha CS (2017) Persistent disparities in Hispanics with cervical cancer in a major city. J Racial Ethn Health Disparities 4:165–168CrossRefPubMed
28.
go back to reference Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236CrossRefPubMed Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236CrossRefPubMed
Metadata
Title
The effects of treatment duration on outcomes of radiation treatment with high-dose-rate brachytherapy in the era of concurrent chemoradiation for cervical carcinoma
Authors
T. W. Chen
N. E. Wandrey
C. S. Ha
Tony Y. Eng
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Radiation Oncology / Issue 3/2018
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-018-0357-4

Other articles of this Issue 3/2018

Journal of Radiation Oncology 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine